PriceTargets.com logo

GSK - GSK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $56.30
  • Forecasted Upside: 13.78%
  • Number of Analysts: 19
  • Breakdown:
  • 3 Sell Ratings
  • 13 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$49.48 As of 10/30/2026 04:59 PM ET
▲ +0.8 (1.64%)

This chart shows the closing price for GSK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GSK Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GSK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GSK

Analyst Price Target is $56.30
▲ +13.78% Upside Potential
This price target is based on 19 analysts offering 12 month price targets for GSK in the last 3 months. The average price target is $56.30, with a high forecast of $70.00 and a low forecast of $43.00. The average price target represents a 13.78% upside from the last price of $49.48.

This chart shows the closing price for GSK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 19 polled investment analysts is to hold stock in GSK. This rating has held steady since May 2026, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 3 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
5/7/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
8/5/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 3 sell ratings
Ratings as of
2/1/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 3 sell ratings
Ratings as of
5/2/2026
  • 1 strong buy ratings
  • 2 buy ratings
  • 11 hold ratings
  • 2 sell ratings
Ratings as of
7/31/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 12 hold ratings
  • 2 sell ratings
Ratings as of
9/29/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 12 hold ratings
  • 3 sell ratings
Ratings as of
10/29/2026

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 13 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/29/2026Jefferies Financial GroupDowngradeBuy ➝ Hold$67.40 ➝ $55.90
10/27/2026Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
10/9/2026Wolfe ResearchInitiated CoverageOutperform$70.00
10/6/2026Berenberg BankReiterated RatingBuy ➝ Buy
10/1/2026JPMorgan Chase & Co.Reiterated RatingSell ➝ Sell
9/29/2026Deutsche Bank AktiengesellschaftReiterated RatingNeutral ➝ Neutral
9/28/2026Jefferies Financial GroupReiterated RatingBuy ➝ Buy
9/15/2026Berenberg BankSet Target$60.00
9/15/2026Berenberg BankUpgradeHold ➝ Buy$54.00 ➝ $60.00
9/10/2026HSBCReiterated RatingHold ➝ Hold
9/8/2026Royal Bank Of CanadaInitiated CoverageOutperform ➝ Sector Perform
9/7/2026BarclaysReiterated RatingSell ➝ Sell
8/25/2026Morgan StanleyReiterated RatingUnderweight ➝ Underweight
8/2/2026Sanford C. BernsteinReiterated RatingBuy ➝ Buy
7/30/2026Deutsche Bank AktiengesellschaftReiterated RatingHold ➝ Hold
7/29/2026Weiss RatingsDowngradeBuy (B-) ➝ Hold (C+)
7/24/2026CitigroupInitiated CoverageNeutral
7/17/2026Jefferies Financial GroupUpgradeBuy ➝ Strong-Buy
7/9/2026Deutsche Bank AktiengesellschaftReiterated RatingHold ➝ Hold
7/6/2026HSBCUpgradeReduce ➝ Hold
6/29/2026The Goldman Sachs GroupReiterated RatingNeutral
6/11/2026Weiss RatingsDowngradeBuy (B) ➝ Buy (B-)
6/9/2026Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform
6/9/2026UBS GroupReiterated RatingNeutral ➝ Neutral
5/14/2026MorningstarUpgradeBuy
5/4/2026Oddo BhfReiterated RatingNeutral ➝ Neutral
5/1/2026Weiss RatingsUpgradeHold (C+) ➝ Buy (B)
4/29/2026DZ BankReiterated RatingNeutral ➝ Neutral
3/19/2026Weiss RatingsDowngradeBuy (B-) ➝ Hold (C+)
2/20/2026BarclaysReiterated RatingUnderweight ➝ Underweight
2/9/2026CitigroupReiterated RatingHold ➝ Neutral
2/9/2026TD CowenReiterated RatingHold ➝ Hold
1/27/2026CitigroupInitiated CoverageBuy ➝ Neutral
1/16/2026Deutsche Bank AktiengesellschaftReiterated RatingHold ➝ Hold
1/14/2026Morgan StanleyReiterated RatingUnderweight ➝ Underweight
1/6/2026BarclaysDowngradeEqual Weight ➝ Underweight
12/29/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
12/22/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
12/15/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
12/10/2025HSBCReiterated RatingReduce ➝ Reduce
12/8/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
12/2/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
11/26/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
11/25/2025Berenberg BankBoost TargetHold ➝ Hold$41.00 ➝ $43.00
11/25/2025Bank of AmericaUpgradeUnderperform ➝ Neutral
11/20/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
10/31/2025Weiss RatingsUpgradeHold (C+) ➝ Buy (B-)
10/30/2025CfraSet Target$53.00
10/27/2025Jefferies Financial GroupReiterated RatingHold ➝ Buy
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
6/3/2025Berenberg BankReiterated RatingBuy ➝ Hold
4/28/2025HSBCUpgradeStrong Sell
4/15/2025BNP Paribas ExaneInitiated CoverageNeutral$35.25
2/12/2025Morgan StanleyInitiated CoverageEqual Weight
11/15/2024Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
11/12/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$53.00 ➝ $39.50
10/31/2024GuggenheimDowngradeBuy ➝ Neutral
8/27/2024BarclaysUpgradeHold
8/7/2024ArgusUpgradeStrong-Buy
7/8/2024UBS GroupDowngradeBuy ➝ Neutral
7/2/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$52.50 ➝ $53.00
6/24/2024CitigroupUpgradeStrong-Buy
6/20/2024Berenberg BankUpgradeStrong-Buy
5/30/2024The Goldman Sachs GroupInitiated CoverageNeutral$47.00
3/4/2024GuggenheimUpgradeNeutral ➝ Buy
2/13/2024CitigroupUpgradeNeutral ➝ Buy
1/23/2024Morgan StanleyInitiated CoverageEqual Weight
1/3/2024Jefferies Financial GroupUpgradeHold ➝ Buy
7/14/2023HSBCInitiated CoverageReduce
3/17/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
2/26/2023The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy
2/10/2023Berenberg BankBoost TargetGBX 1,580 ➝ GBX 1,730
2/2/2023JPMorgan Chase & Co.Boost TargetGBX 1,350 ➝ GBX 1,400
1/3/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
12/8/2022AlphaValueUpgradeBuy
12/5/2022Bank of AmericaDowngradeNeutral ➝ Underperform
12/2/2022CitigroupLower TargetGBX 1,975 ➝ GBX 1,550
11/30/2022Morgan StanleyLower TargetGBX 1,650 ➝ GBX 1,535
11/11/2022UBS GroupDowngradeNeutral ➝ Sell
11/8/2022JPMorgan Chase & Co.Lower TargetGBX 1,900 ➝ GBX 1,600
10/14/2022BarclaysLower TargetGBX 1,800 ➝ GBX 1,450
10/12/2022Morgan StanleyBoost TargetGBX 1,550 ➝ GBX 1,650
9/29/2022Oddo BhfUpgradeNeutral ➝ Outperform
9/15/2022Credit Suisse GroupUpgradeUnderperform ➝ Neutral
9/8/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
9/7/2022Deutsche Bank AktiengesellschaftLower TargetGBX 1,750 ➝ GBX 1,500
9/7/2022Morgan StanleyLower TargetGBX 1,860 ➝ GBX 1,550
8/5/2022Morgan StanleyReiterated RatingEqual Weight
7/21/2022CitigroupReiterated RatingNeutral
7/20/2022UBS GroupLower TargetGBX 1,876 ➝ GBX 1,850
7/19/2022AlphaValueDowngradeReduce
7/15/2022Credit Suisse GroupBoost TargetGBX 1,400 ➝ GBX 1,600
4/29/2022BarclaysBoost TargetGBX 1,775 ➝ GBX 1,800
4/28/2022JPMorgan Chase & Co.Boost TargetGBX 1,740 ➝ GBX 1,900
4/14/2022BarclaysBoost TargetGBX 1,675 ➝ GBX 1,775
2/28/2022Stifel NicolausInitiated CoverageHold
2/11/2022DZ BankDowngradeBuy ➝ Hold
11/24/2021Berenberg BankReiterated RatingBuy
11/8/2021UBS GroupReiterated RatingNeutral
11/5/2021BarclaysUpgradeUnderweight ➝ Equal Weight
11/3/2021Morgan StanleyReiterated RatingEqual Weight
11/1/2021JPMorgan Chase & Co.Reiterated RatingNeutral
(Data available from 10/30/2021 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 17 very positive mentions
  • 18 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
5/3/2026
  • 13 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2026
  • 27 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 4 very negative mentions
Mentions as of
7/2/2026
  • 15 very positive mentions
  • 30 positive mentions
  • 9 negative mentions
  • 1 very negative mentions
Mentions as of
8/1/2026
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
8/31/2026
  • 15 very positive mentions
  • 18 positive mentions
  • 8 negative mentions
  • 9 very negative mentions
Mentions as of
9/30/2026
  • 31 very positive mentions
  • 35 positive mentions
  • 12 negative mentions
  • 4 very negative mentions
Mentions as of
10/30/2026

Current Sentiment

  • 31 very positive mentions
  • 35 positive mentions
  • 12 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

GSK logo
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Read More

Today's Range

Now: $49.48
Low: $49.25
High: $50.28

50 Day Range

MA: $49.44
Low: $46.24
High: $52.52

52 Week Range

Now: $49.48
Low: $45.81
High: $61.69

Volume

4,767,272 shs

Average Volume

5,910,561 shs

Market Capitalization

$100.08 billion

P/E Ratio

10.25

Dividend Yield

3.64%

Beta

0.33

Frequently Asked Questions

What sell-side analysts currently cover shares of GSK?

The following Wall Street sell-side analysts have issued reports on GSK in the last twelve months: Bank of America Corporation, Barclays PLC, Berenberg Bank, Cfra, Citigroup Inc., Deutsche Bank Aktiengesellschaft, DZ Bank AG, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Morningstar, Inc., Oddo Bhf, Royal Bank Of Canada, Sanford C. Bernstein, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, Wall Street Zen, Weiss Ratings, and Wolfe Research.
View the latest analyst ratings for GSK.

What is the current price target for GSK?

0 Wall Street analysts have set twelve-month price targets for GSK in the last year. Their average twelve-month price target is $56.30, suggesting a possible upside of 13.7%. Wolfe Research has the highest price target set, predicting GSK will reach $70.00 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of $43.00 for GSK in the next year.
View the latest price targets for GSK.

What is the current consensus analyst rating for GSK?

GSK currently has 3 sell ratings, 13 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GSK, but not buy more shares or sell existing shares.
View the latest ratings for GSK.

What other companies compete with GSK?

Other companies that are similar to GSK include Merck & Co., Inc., Novartis, AstraZeneca, Novo Nordisk A/S and Pfizer. Learn More about companies similar to GSK.

How do I contact GSK's investor relations team?

GSK's physical mailing address is 79 New Oxford Street, London, GL, WC1A 1DG. The pharmaceutical company's listed phone number is 442080475000 and its investor relations email address is [email protected]. The official website for GSK is www.gsk.com. Learn More about contacing GSK investor relations.